ATLAS News · Companies

Hims & Hers Health Reports Q3 Results and Lilly Weight-Loss Drug Partnership

Published November 12, 2026 · 4 sources

Hims & Hers Health (HIMS) posted its Q3 2026 earnings presentation, and Yahoo Finance reports a Lilly partnership for FDA-approved weight-loss drugs.

What happened

Hims & Hers Health (NYSE: HIMS) released its earnings call presentation for the third quarter of 2026 on November 12, according to Seeking Alpha. Yahoo Finance reports that the company has partnered with Lilly to offer FDA-approved weight-loss drugs.

Simply Wall St discusses the company's obesity deal and asks whether the current valuation can be explained by its sales. It notes that shareholders have recently seen a volatile ride and that the stock has delivered a total return of 166.3% over the past 5 years.

Yahoo Finance also describes HIMS as a trending stock, in a piece that lays out facts for investors to know about the company.

Context

Hims & Hers Health operates a telehealth platform, and weight-loss treatments are one of the areas drawing attention to the company.

Why it matters

The Lilly partnership and the quarterly results give investors new information for assessing the company's business and how its valuation relates to its sales.

Stocks in this story

Price changes are shown for the trading day of the story and are a coincidence in time, not proof that the news caused them. Figures are ATLAS data from our database.

Hims & Hers HealthHIMS

−5.19%

Healthcare · NYSE

Live price

$19.89▼ -5.19%

live price · USD

Close on November 12: $19.73−5.19% vs. previous close ($20.81)
Fair value (ATLAS): $25.75Fair range: $5.83 to $42.25The price ($19.89) is 22.8% below that figure.
Chance of a rise in 1 month: 44%Probability of closing higher than today within 21 sessions.Normal range: half of the scenarios end between $15.90 and $22.92; 9 in 10, between $11.50 and $31.69.

See the full ATLAS analysis of Hims & Hers Health →

Closing prices, fair value and probabilities: ATLAS own data. How we calculate fair value.

Sources

ATLAS writes its own summaries from the reporting of these outlets. Each link opens the original publisher.

Hims & Hers Health, Inc. 2026 Q3 - Results - Earnings Call Presentation (NYSE:HIMS) 2026-11-12 · Seeking Alpha · November 12, 2026
Can Hims & Hers Health (HIMS) Stay Cheap After Its Obesity Deal? · Simply Wall St · November 13, 2026
Hims & Hers Health, Inc. (HIMS) Is a Trending Stock: Facts to Know Before Betting on It · Yahoo Finance · November 13, 2026
HIMS Partners With Lilly to Offer FDA-Approved Weight-Loss Drugs · Yahoo Finance · November 13, 2026

Latest market news · Markets today on ATLAS · Hims & Hers Health

What you get with ATLAS

Create my ATLAS account →

Fair value, probabilities and earnings for every stock. Free account, no card. Information, not advice.

Information, not advice. This content is informational and is not an investment recommendation or an offer to buy or sell securities. ATLAS estimates come from statistical models using public data, can be wrong, and past performance does not guarantee future results. Disclaimer